Verici Dx 

Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. It also offers sequencing services for tumor-only, tumor-normal, and germline exomes; whole transcriptome, targeted RNASeq and ncRNAs, and functional binding multicell assay. In addition, the company provides bioinformatics and data science services for exome analysis options; RNA pipeline; multiomic signature discovery, TCR clonotype antigen identification, custom pipeline building, and predictive modeling; and simulation of 100s of drug combinations against multiomic personalized tumor models. It has collaborations with One Lambda Inc. for the commercialization of pre transplant risk assessment (PTRA), a pre-transplant prognosis test for the risk of early acute rejection; The Westmead Institute for Medical Research to determine the factors contributing to graft loss in organ transplants; and FBB Biomed, Inc., which provides research-use-only tests for clinicians seeking insights into neurologic diseases, such as multiple sclerosis and long COVID. Verici Dx plc was incorporated in 2020 and is based in Cardiff, the United Kingdom.